Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SLP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.25
1 Year Target Price $36.25
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.7% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 339.07M USD | Price to earnings Ratio 46.83 | 1Y Target Price 36.25 |
Price to earnings Ratio 46.83 | 1Y Target Price 36.25 | ||
Volume (30-day avg) 6 | Beta 0.97 | 52 Weeks Range 16.72 - 44.26 | Updated Date 06/30/2025 |
52 Weeks Range 16.72 - 44.26 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 1.43% | Basic EPS (TTM) 0.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-06-30 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin 9.24% | Operating Margin (TTM) 11.64% |
Management Effectiveness
Return on Assets (TTM) 1.98% | Return on Equity (TTM) 3.96% |
Valuation
Trailing PE 46.83 | Forward PE 52.91 | Enterprise Value 318080997 | Price to Sales(TTM) 4.32 |
Enterprise Value 318080997 | Price to Sales(TTM) 4.32 | ||
Enterprise Value to Revenue 4.05 | Enterprise Value to EBITDA 27.48 | Shares Outstanding 20111000 | Shares Floating 16598249 |
Shares Outstanding 20111000 | Shares Floating 16598249 | ||
Percent Insiders 17.45 | Percent Institutions 85.11 |
Analyst Ratings
Rating 3 | Target Price 36.25 | Buy - | Strong Buy 5 |
Buy - | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus Inc. was founded in 1996. It has grown from a provider of GastroPlus software to a leading developer of simulation and modeling software for drug discovery and development. The company has expanded its offerings through strategic acquisitions and organic growth, focusing on physiologically-based pharmacokinetic (PBPK) modeling, quantitative systems pharmacology (QSP) and ADMET simulation.
Core Business Areas
- Simulations Plus Software: Develops and markets software for simulating drug behavior, including GastroPlus, ADMET Predictor, DDDPlus, MembranePlus, and PKPlus. These tools aid in predicting drug absorption, distribution, metabolism, excretion, and toxicity.
- Consulting Services: Provides scientific consulting services utilizing its software and expertise to assist pharmaceutical and biotechnology companies in drug development. This includes model building, simulations, and data analysis.
- Software Maintenance and Support: Offers ongoing maintenance, support, and training services for its software products.
Leadership and Structure
Shawn O'Connor serves as CEO. The company has a board of directors and operates through various functional departments including software development, sales, marketing, and consulting.
Top Products and Market Share
Key Offerings
- GastroPlus: A physiologically-based pharmacokinetic (PBPK) modeling platform used to simulate drug absorption and bioavailability. Simulations Plus holds a significant market share (estimated 60-70%) in the PBPK modeling software market. Competitors include Certara (Simcyp) and Open Systems Pharmacology (PK-Sim). Significant revenue driver, no exact value available.
- ADMET Predictor: Software that predicts absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of drug candidates. Competitors include Schrodinger and Instem (Metabolite). ADMET Predictor has substantial revenue contribution, though precise market share data isn't publicly available. Market share is estimated at 20-30%.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries increasingly rely on simulation and modeling software to accelerate drug development, reduce costs, and improve decision-making. Regulatory agencies are also encouraging the use of PBPK models in drug approval processes.
Positioning
Simulations Plus is a leading provider of PBPK and ADMET modeling software. It is known for its scientifically rigorous models, ease of use, and strong customer support. The company benefits from increasing adoption of modeling and simulation technologies in the pharmaceutical industry.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical simulation software is estimated to be in the hundreds of millions of dollars annually and growing. Simulations Plus is well positioned to capture a significant share of this market due to its established reputation and comprehensive product portfolio.
Upturn SWOT Analysis
Strengths
- Established reputation and brand recognition
- Scientifically validated and accurate models
- Strong customer support and training
- Diverse product portfolio
- Long-standing relationships with pharmaceutical companies
Weaknesses
- Dependence on the pharmaceutical industry
- Potential for model inaccuracies
- Pricing can be a barrier for smaller companies
- Limited brand awareness outside of the pharma market
- Relatively small market capitalization compared to major competitors.
Opportunities
- Expanding into new therapeutic areas
- Developing new software modules and features
- Growing demand for PBPK modeling
- Strategic partnerships with other technology providers
- Increase in regulatory requirements for modeling and simulation
Threats
- Competition from larger companies with more resources
- Technological obsolescence
- Economic downturn impacting pharmaceutical R&D spending
- Changes in regulatory guidelines
- Open source/free alternatives gaining traction
Competitors and Market Share
Key Competitors
- Certara (None)
- Schru00f6dinger (SDGR)
- Instem (Not Publicly Traded in the US)
Competitive Landscape
Simulations Plus competes with larger companies like Certara and Schru00f6dinger. Its advantage lies in its specialized expertise and customer focus. However, its resources are smaller compared to its larger competitors.
Major Acquisitions
Cognigen Corporation
- Year: 2018
- Acquisition Price (USD millions): 37.2
- Strategic Rationale: Expanded consulting services and added expertise in quantitative systems pharmacology (QSP).
DILIsym Services, Inc.
- Year: 2023
- Acquisition Price (USD millions): 17
- Strategic Rationale: Augments the portfolio of quantitative systems toxicology (QST) for the company, furthering it into that market space.
Growth Trajectory and Initiatives
Historical Growth: Simulations Plus has achieved consistent revenue growth over the past decade, primarily driven by increased adoption of its PBPK and ADMET modeling software.
Future Projections: Analysts project continued revenue and earnings growth for Simulations Plus, driven by increasing demand for simulation and modeling technologies in the pharmaceutical industry. Projected to outpace market average growth.
Recent Initiatives: Simulations Plus has focused on expanding its software portfolio through acquisitions and developing new modules for existing products. It is also investing in sales and marketing to reach new customers.
Summary
Simulations Plus is a strong company with a leading position in the pharmaceutical simulation software market. It benefits from increasing demand for its products and services, driven by regulatory and industry trends. The company should be cautious of competition and needs to maintain its innovative edge. Simulations Plus' future outlook appears positive, provided it continues to meet the evolving needs of its customers.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Simulations Plus Investor Relations
- Company SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on available information and represents an opinion, not financial advice. Market conditions and company performance are subject to change. Market share is an estimate and is not guaranteed to be perfectly accurate. Financial data and information can be found on SLP 10k SEC filings
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Lancaster, CA, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 243 | Website https://www.simulations-plus.com |
Full time employees 243 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.